Larimar Therapeutics, Inc. (LRMR)

NGM – Real vaqt narxi. Valyuta: USD

4.13

+0.04 (0.98%)

Yopilishda: May 12, 2026, 4:00 PM EDT

4.03

-0.10 (-2.42%)

Bozor oldidan: May 13, 2026, 6:52 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Larimar Therapeutics, Inc. (LRMR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videolar

No Data

Press-relizlar

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026

Search stocks

Larimar Therapeutics, Inc. (LRMR)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Larimar Therapeutics, Inc. (LRMR)

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

2 Breakout Stocks to Buy Immediately

LRMR Stock on the Move: What Sparked the 55% Jump in the Past Month?

Larimar Therapeutics to Participate in Upcoming Investor Conferences in March

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Laminar Therapeutics Stock Is Popping Today: What's Going On?

Videolar

No Data

Press-relizlar

Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering

Larimar Therapeutics Announces FDA Breakthrough Therapy Designation for Nomlabofusp in FA and Reiterates Planned BLA Submission in June 2026